Expected epidemiological impacts of introducing an HIV vaccine in Thailand: A model-based analysis

Vaccine

Volumn 29, Issue 36, 2011, Pages 6086-6091

  Schneider, Karen ^a   Kerr, Cliff C ^a   Hoare, Alexander ^a   Wilson, David P ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

HIV; Mathematical model; RV144; Thailand; Vaccine

Indexed keywords

ERDOSTEINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RV 144 LIKE VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PRIORITY JOURNAL; REVACCINATION; THAILAND; VACCINATION;

ADOLESCENT; ADULT; AIDS VACCINES; CLINICAL TRIALS AS TOPIC; FEMALE; HIV; HIV INFECTIONS; HUMANS; IMMUNIZATION PROGRAMS; MALE; MIDDLE AGED; MODELS, THEORETICAL; PREVALENCE; PUBLIC HEALTH; SEX WORKERS; THAILAND; TREATMENT OUTCOME; VACCINATION; YOUNG ADULT;

EID: 80051471105     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.074     Document Type: Article

References (18)

1. Barouch D.H. Challenges in the development of an HIV-1 vaccine. Nature 2008, 455(7213):613-619.
2. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F., et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005, 191(5):654-665.
3. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194(12):1661-1671.
4. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372(9653):1881-1893.
5. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(23):2209-2220.
6. Amirfar S., Hollenberg J.P., Abdool Karim S.S. Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa. J Acquir Immune Defic Syndr 2006, 43:219-225.
7. Blower S.M., Koelle K., Kirschner D.E., Mills J. Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety. Proc Natl Acad Sci USA 2001, 98(March 13 (6)):3618-3623.
8. Bogard E., Kuntz K.M. The impact of a partially effective HIV vaccine on a population of intravenous drug users in Bangkok, Thailand: a dynamic model. J Acquir Immune Defic Syndr 2002, 29:132-141.
9. Blower S., McLean A. Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. Science 1994, 265(5177):1451-1454.
10. Anderson R.M., Swinton J., Garnett G.P. Potential impact of low efficacy HIV-1 vaccines in populations with high rates of infection. Proc Biol Sci 1995, 261(1361):147-151.
11. National AIDS Prevention and Alleviation Committee. UNGASS Country progress report Thailand. Reporting period January 2008-December 2009. Available from: ; 2010. http://www.tncathai.org/data/data13.pdf.
12. Coleman T.F., Li Y. An interior, trust region approach for nonlinear minimization subject to bounds. SIAM J Optimiz 1996, 6:418-445.
13. Blower S.M., Dowlatabadi H. Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int Stat Rev 1994, 2:229-324.
14. Hoare A., Regan D.G., Wilson D.P. Sampling and sensitivity analyses tools (SaSAT) for computational modelling. Theor Biol Med Model 2008, 5(1):4.
15. UNAIDS/WHO Working Group on Global HIV/AIDS and STI. Epidemiological fact sheet on HIV and AIDS. Core data on epidemiology and response. Thailand. 2008 Update. Geneva: UNAIDS/WHO. Available from: ; 2008. http://apps.who.int/globalatlas/predefinedReports/EFS2008/full/EFS2008_TH.pdf.
16. Wilson D.P. Interpreting sexually transmissible infection prevention trials by adjusting for the magnitude of exposure. Clin Trials 2010, 7:36-43.
17. Newman P.A., Logie C. HIV vaccine acceptability: a systematic review and meta-analysis. AIDS 2010, 24(11):1749-1756.
18. Kaldor J.M., Wilson D.P. How low can you go: the impact of a modestly effective HIV vaccine compared with male circumcision. AIDS 2010, 24(16):2573-2578.